TY - JOUR
AU - Michetti,, Fabrizio
AB - Intrauterine growth retardation (IUGR) is thought to reflect suppression of genetic growth potential by decreased supplies of oxygen and substrate (1). NO supplementation may be useful in IUGR to increase uteroplacental circulation (2)(3)(4)(5). The use of biochemical markers to assess the extent of brain distress associated with NO treatment could be appropriate. S100B is an acidic calcium-binding protein of the EF-hand family concentrated in the nervous system (6). The appearance of S100B in biological fluids is an indicator of brain distress in both infants and adults (7)(8)(9)(10). Recently, blood S100B concentrations in the perinatal period have been shown to correlate with brain maturation and damage (11)(12)(13)(14). We investigated the effect of maternal NO supplementation on brain distress in IUGR fetuses as assessed by cord blood S100B. We selected 51 pregnant women (gestational age, 27–35 weeks) with IUGR fetuses and impaired uteroplacental blood flow. Exclusion criteria included multiple pregnancies, gestational and type 1 diabetes, maternal infections and fever, fetal malformations and chromosomal abnormalities, metabolic diseases, and maternal diseases of the central nervous system. Patients were assigned, by use of computer-generated random numbers, to receive either placebo (n = 25) or transdermal glyceryl trinitrate (Nitroderm TTS; Ciba-Geigy) at a dose of 5 mg/16 h daily until delivery (n = 26). Placebo and glyceryl trinitrate patches were indistinguishable and were numbered and contained in identical envelopes so that patients did not know the group to which they were recruited. Similarly, neither the physicians nor the investigators who analyzed the samples knew which patients were treated with placebo and which with glyceryl trinitrate patches. The local ethics committee approved the study, and written informed consent was obtained from all participants. Two patients in the glyceryl trinitrate group declined to accept administration of the drug, and one did not follow correctly the indications for patch application and was removed from the data analysis. Gestational age at the time of enrollment did not differ between the two groups. All fetuses were delivered by elective cesarean section for obstetrical reasons and did not experience uterine contractility. Gestational ages were determined by clinical data and by a first-trimester ultrasound scan. IUGR was defined by the presence of ultrasonographic signs (biparietal diameter below the 10th centile and abdominal circumference below the 5th percentile) according to the normograms of Campbell and Thoms (15) and by a fall in the centile of fetal size recorded between the first scan after referral and subsequent scans. The flow velocity waveforms (FVWs) of the main branch of the uterine artery bilaterally, the umbilical artery (UA), and fetal middle cerebral artery (MCA) were recorded by means of a duplex pulsed color Doppler ultrasound (SSD-2000; Aloka). A reading >2 SD above the mean for the gestational age in uncomplicated pregnancies was defined as a pathologic resistance index (RI) for the uterine artery and as a pathologic pulsatility index (PI) for the UA. An abnormal PI in the FVWs of the fetal MCA was defined as a pathologic RI for −2 SD from the mean for that particular gestational age in uncomplicated pregnancies. A UA/MCA PI ratio >1 was considered pathologic. The control group consisted of 20 apparently healthy fetuses matched for gestational age at sampling and with birth weights between the 10th and 90th percentiles, delivered by elective cesarean section, and not experiencing uterine contractility. In these infants, the FVWs of the MCAs were not recorded because they had normal velocimetry waveforms in the uterine and umbilical arteries. Maternal blood samples were collected from the groups studied before and after the administration of a patch (glyceryl trinitrate or placebo). In the control group, blood was drawn before the induction of anesthesia. Immediately after delivery, the umbilical cord was clamped before any signs of breathing were detected, and blood was drawn from the vein. Heparin-treated blood samples taken from the umbilical cord at birth were immediately centrifuged at 900g for 10 min, and the supernatants were stored at −70 °C. The S100B concentration was measured in all samples by a commercially available IRMA (Sangtec® 100; AD Sangtec Medical) specific to the β subunit of the protein, which is known to predominate (80–96%) in the human brain (16)(17). Each measurement was performed in duplicate, and the means were reported. The limit of detection was 0.2 μg/L. Neonatal neurologic outcome was assessed on the 7th day from birth by a qualitative approach similar to that described by Prechtl (18). Each infant was assigned to one of three diagnostic groups: normal, suspect, or abnormal. The same examiner, who did not know the neurologic condition at birth, tested all infants. NO metabolites (NOx) and S100B concentrations were expressed as mean values ± SD. Statistical analysis was performed using the Spearman rank-order correlation. Groups were compared using the Kruskal–Wallis one-way ANOVA, with the Mann–Whitney U-test used when data were not normally distributed. Comparison between the incidences of neonatal neurologic outcome and of acute respiratory distress syndrome was performed with the Fisher exact test. Maternal NOx and S100B values before and after treatment were compared using the Student t-test for paired data. The clinical characteristics of the women are expressed as means ± SD and were compared by unpaired data. Statistical significance was set at P <0.05. Uteroplacental and fetal Doppler findings in the groups studied are shown in Table 1. Transdermal glyceryl trinitrate administration was associated with a significant decrease in uterine artery RI and the UA PI (P <0.05), whereas no significant difference was found in MCA PI (P >0.05). Because of the reduction in the UA PI, the UA/MCA PI ratio decreased significantly (P <0.05) after NO administration. In the placebo group, FVWs worsened with a significant increase in the uterine artery RI (P <0.05), leading to elective cesarean section. This produced a higher mean gestational age at delivery in the treated than in the placebo group. NOx and S100B concentrations in maternal plasma before and after treatment were not significantly different (P >0.05). Maternal S100B and NOx measurements did not correlate with UA PI in both the NO-treated and the untreated group (P >0.05). NOx and S100B protein in maternal plasma measured at the time of elective cesarean section did not differ between the IUGR and control groups (P >0.05). Table 1. Characteristics of pregnant women studied. . Placebo1 (n = 25) . NO-treated1 (n = 23) . Maternal age, years 28 ± 2 27 ± 3 Gestational age at birth, weeks 38 ± 2 33 ± 12 Birth weight, kg 1.89 ± 0.43 1.82 ± 0.58 Apgar  1 min 8.1 ± 2 8.2 ± 2  5 min 8.5 ± 1 8.8 ± 1 Respiratory distress syndrome, n 7/25 13/232 Neurologic abnormalities, n 9/25 2/232 Uterine artery RI  Before administration 0.81 ± 0.05 0.83 ± 0.03  After administration 0.87 ± 0.09 0.64 ± 0.082 UA PI  Before administration 1.5 ± 0.1 1.5 ± 0.2  After administration 1.6 ± 0.1 1.3 ± 0.12 MCA PI  Before administration 1.4 ± 0.1 1.4 ± 0.1  After administration 1.4 ± 0.1 1.4 ± 0.1 UA/MCA PI ratio  Before administration 1.1 ± 0.1 1.1 ± 0.1  After administration 1.2 ± 0.1 0.9 ± 0.12 Fetal plasma NOx, mol/L 23 ± 6 22 ± 3 . Placebo1 (n = 25) . NO-treated1 (n = 23) . Maternal age, years 28 ± 2 27 ± 3 Gestational age at birth, weeks 38 ± 2 33 ± 12 Birth weight, kg 1.89 ± 0.43 1.82 ± 0.58 Apgar  1 min 8.1 ± 2 8.2 ± 2  5 min 8.5 ± 1 8.8 ± 1 Respiratory distress syndrome, n 7/25 13/232 Neurologic abnormalities, n 9/25 2/232 Uterine artery RI  Before administration 0.81 ± 0.05 0.83 ± 0.03  After administration 0.87 ± 0.09 0.64 ± 0.082 UA PI  Before administration 1.5 ± 0.1 1.5 ± 0.2  After administration 1.6 ± 0.1 1.3 ± 0.12 MCA PI  Before administration 1.4 ± 0.1 1.4 ± 0.1  After administration 1.4 ± 0.1 1.4 ± 0.1 UA/MCA PI ratio  Before administration 1.1 ± 0.1 1.1 ± 0.1  After administration 1.2 ± 0.1 0.9 ± 0.12 Fetal plasma NOx, mol/L 23 ± 6 22 ± 3 1 Mean ± SD 2 P <0.05. Open in new tab Table 1. Characteristics of pregnant women studied. . Placebo1 (n = 25) . NO-treated1 (n = 23) . Maternal age, years 28 ± 2 27 ± 3 Gestational age at birth, weeks 38 ± 2 33 ± 12 Birth weight, kg 1.89 ± 0.43 1.82 ± 0.58 Apgar  1 min 8.1 ± 2 8.2 ± 2  5 min 8.5 ± 1 8.8 ± 1 Respiratory distress syndrome, n 7/25 13/232 Neurologic abnormalities, n 9/25 2/232 Uterine artery RI  Before administration 0.81 ± 0.05 0.83 ± 0.03  After administration 0.87 ± 0.09 0.64 ± 0.082 UA PI  Before administration 1.5 ± 0.1 1.5 ± 0.2  After administration 1.6 ± 0.1 1.3 ± 0.12 MCA PI  Before administration 1.4 ± 0.1 1.4 ± 0.1  After administration 1.4 ± 0.1 1.4 ± 0.1 UA/MCA PI ratio  Before administration 1.1 ± 0.1 1.1 ± 0.1  After administration 1.2 ± 0.1 0.9 ± 0.12 Fetal plasma NOx, mol/L 23 ± 6 22 ± 3 . Placebo1 (n = 25) . NO-treated1 (n = 23) . Maternal age, years 28 ± 2 27 ± 3 Gestational age at birth, weeks 38 ± 2 33 ± 12 Birth weight, kg 1.89 ± 0.43 1.82 ± 0.58 Apgar  1 min 8.1 ± 2 8.2 ± 2  5 min 8.5 ± 1 8.8 ± 1 Respiratory distress syndrome, n 7/25 13/232 Neurologic abnormalities, n 9/25 2/232 Uterine artery RI  Before administration 0.81 ± 0.05 0.83 ± 0.03  After administration 0.87 ± 0.09 0.64 ± 0.082 UA PI  Before administration 1.5 ± 0.1 1.5 ± 0.2  After administration 1.6 ± 0.1 1.3 ± 0.12 MCA PI  Before administration 1.4 ± 0.1 1.4 ± 0.1  After administration 1.4 ± 0.1 1.4 ± 0.1 UA/MCA PI ratio  Before administration 1.1 ± 0.1 1.1 ± 0.1  After administration 1.2 ± 0.1 0.9 ± 0.12 Fetal plasma NOx, mol/L 23 ± 6 22 ± 3 1 Mean ± SD 2 P <0.05. Open in new tab In fetal plasma, NOx concentrations were similar in the three groups: 27.5 ± 5.2 mol/L in controls, 22.6 ± 5.5 mol/L in the placebo group, and 21.6 ± 2.9 mol/L in the treated group (P >0.05). No correlation was found between maternal and fetal concentrations in any group (P >0.05). Fetal S100B concentrations were significantly higher in the placebo IUGR group (3.73 ± 1.63 μg/L) when compared with the NO-treated IUGR group (0.91 ± 0.43 μg/L) and controls (1.54 ± 0.72 μg/L; P <0.05), whereas no differences were observed between the NO-treated IUGR group and controls (P >0.05; Fig. 1). S100B concentrations correlated with the MCA PI in untreated growth-retarded fetuses (r = 0.64; P <0.01), but not in the NO-treated IUGR group (P >0.05). We found no significant correlations between maternal or fetal S100B and NOx concentrations in any group (P >0.05). Figure 1. Open in new tabDownload slide S100B protein cord blood concentrations in controls and in the placebo and NO-treated groups. The top and bottom bars represent the 10th and 90th centiles, respectively, and the boxes represent the interquartile ranges, with the median values being the horizontal lines inside the boxes. S100B concentrations were significantly higher (∗, P <0.05) in umbilical plasma from the placebo group than in the control and in treated groups. Figure 1. Open in new tabDownload slide S100B protein cord blood concentrations in controls and in the placebo and NO-treated groups. The top and bottom bars represent the 10th and 90th centiles, respectively, and the boxes represent the interquartile ranges, with the median values being the horizontal lines inside the boxes. S100B concentrations were significantly higher (∗, P <0.05) in umbilical plasma from the placebo group than in the control and in treated groups. At birth, as expected, gestational age, placental weight, and birth weight were significantly higher in the control group (P <0.05). Apgar scores evaluated at 1 and 5 min were similar in the three groups. No significant differences between placebo and treated groups were observed in birth weight or Apgar scores at 1 or 5 min (P >0.05), but gestational age was significantly higher in the treated group (P <0.05). The incidences of adverse neonatal neurologic outcome and respiratory distress syndrome were significantly lower in the treated groups (P <0.05). The clinical and monitoring parameters evaluated in the present study are consistent with previous observations indicating that transdermal glyceryl trinitrate administration improves uteroplacental perfusion, the quality of the pregnancy, and short-term neonatal outcome (2)(3)(4)(5). As reported for other NO donors, long-term administration of NO donors to the mother does not affect maternal plasma NO concentrations (5)(19). Nitroglycerin has a low molecular weight and rapidly crosses the placenta, directly affecting placental and fetal compartments. The present research shows that S100B, a well-established biochemical marker of brain distress, is significantly decreased in the cord blood of IUGR fetuses after maternal treatment with a NO donor. The concentrations of S100B detected in the NO-treated group in this study were essentially superimposable on those of preterm healthy fetuses in a previous study (11). The significantly higher S100B concentrations in IUGR fetuses of the placebo group compared with preterm controls support the view that the increase did not reflect a lower gestational age. The high cord blood S100B concentrations observed in IUGR fetuses whose mothers were not treated with NO offer laboratory support for the notion that fetal brain distress may lead to neonatal brain damage even when fetal hemodynamic adaptive mechanisms are present. This finding is relevant because redistribution in fetal circulation during IUGR is commonly regarded as neuroprotective (2)(3)(4)(5)(20). S100B may be released in the nervous system as a cytokine with a neurotropic role at low concentrations and a neurotoxic role at high concentrations (6). Changes in S100B concentrations measured in the cord blood of IUGR fetuses that have been treated with NO may reflect, at least in part, a relevant role of S100B in the cascade of events accompanying brain distress. S100B may also be released from other sites in which S100B is concentrated, such as adipose tissue, although data on the presence of the protein in adipose tissue at this age have not been published. In conclusion, these findings suggest a simple and valuable tool to assess, at birth, both fetal brain distress accompanying IUGR and the positive effects of NO administration. This work was partially supported by grants from Università Cattolica S. Cuore and MURST (to F.M.) and from the “Let’s Improve Prenatal Life” Foundation (to D.G.). We also thank Byk Goulden Italia for supplying analytical reagent sets. References 1 Bates JA, Evans JA, Mason G. Differentiation of growth retarded from normally grown fetuses and prediction of intrauterine growth retardation using Doppler ultrasound. Br J Obstet Gynaecol 1996 ; 103 : 670 -675. Crossref Search ADS PubMed 2 Lyall F, Greer IA, Young A, Myatt L. Nitric oxide concentrations are increased in the feto-placental circulation in intrauterine growth restriction. Placenta 1996 ; 17 : 165 -168. Crossref Search ADS PubMed 3 Di Iorio R, Marinoni E, Coacci F, La Torre R, Cosmi EV. Amniotic fluid nitric oxide and uteroplacental blood flow in pregnancy complicated by intrauterine growth retardation. Br J Obstet Gynaecol 1997 ; 104 : 1134 -1139. Crossref Search ADS PubMed 4 Cacciatore B, Halmesmaki E, Kaaja R, Teramo K, Ylikorkala O. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998 ; 179 : 140 -145. Crossref Search ADS PubMed 5 Grunewald C, Kublickas M, Carlström K, Lunell N-O, Nisell H. Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia. Obstet Gynecol 1995 ; 86 : 600 -604. Crossref Search ADS PubMed 6 Zimmer D, Cornwall EH, Landar A, Song W. The S100 protein family: history, function and expression. Brain Res Bull 1995 ; 37 : 417 -429. Crossref Search ADS PubMed 7 Michetti F, Massaro A, Murazio M. The nervous system-specific S100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. Neurosci Lett 1979 ; 11 : 171 -175. Crossref Search ADS PubMed 8 Michetti F, Massaro A, Russo G, Rigon G. The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. J Neurol Sci 1980 ; 44 : 259 -263. Crossref Search ADS PubMed 9 Gazzolo D, Vinesi P, Geloso MC, Marcelletti CF, Iorio FS, Marianeschi SM, et al. S100 blood concentrations in children subjected to cardiopulmonary by-pass. Clin Chem 1998 ; 44 : 1058 -1060. Crossref Search ADS PubMed 10 Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, et al. S100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous tissue. Stroke 1987 ; 18 : 911 -918. Crossref Search ADS PubMed 11 Gazzolo D, Vinesi P, Marinoni E, Di Iorio R, Marras M, Lituania M, et al. S100B protein concentrations in cord blood: correlations with gestational age in term and preterm deliveries. Clin Chem 2000 ; 46 : 998 -1000. Crossref Search ADS PubMed 12 Gazzolo D, Vinesi P, Bartocci M, Geloso MC, Bonacci W, Serra G, et al. Increased S100 blood level as early indicators of intraventricular hemorrhage in preterm infants. Correlation with cerebral Doppler velocimetry. J Neurol Sci 1999 ; 170 : 32 -35. Crossref Search ADS PubMed 13 Gazzolo D, Bruschettini M, Lituania M, Serra G, Gandullia E, Michetti F. S100B protein concentrations in urine are correlated with gestational age in healthy preterm and term newborns. Clin Chem 2001 ; 47 : 1132 -1133. Crossref Search ADS PubMed 14 Gazzolo D, Bruschettini M, Lituania M, Serra G, Bonacci W, Michetti F. Urinary S100B protein as an early indicator of intraventricular hemorrhage in preterm infants: correlation with the grade of hemorrhage. Clin Chem 2001 ; 47 : 1836 -1838. Crossref Search ADS PubMed 15 Campbell S, Thoms A. Ultrasound measurement of the fetal head to abdomen circumference ratio in the assessment of growth retardation. Br J Obstet Gynaecol 1977 ; 84 : 165 -174. Crossref Search ADS PubMed 16 Jensen R, Marshak DR, Anderson C, Lukas TJ, Watterson DM. Characterization of human brain S100 protein fraction: amino acid sequence of S100β. J Neurochem 1985 ; 45 : 700 -705. Crossref Search ADS PubMed 17 Baudier J, Glasser N, Haglid K, Gerard D. Purification, characterization and ion binding properties of human brain S100b protein. Biochim Biophys Acta 1984 ; 790 : 164 -173. Crossref Search ADS PubMed 18 Prechtl HFR. Assessment methods for the newborn infant: a critical evaluation. Stratton D eds. Psychobiology of human newborn 1982 : 21 -52 Wiley Chichester. . 19 Facchinetti F, Longo M, Piccinini F, Neri I, Volpe A. l-Arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Investig 1999 ; 6 : 202 -207. PubMed 20 Bewley S, Campbell S, Cooper D. Doppler investigation of utero-placental blood flow in the second trimester: a screening study for pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1991 ; 98 : 871 -879. Crossref Search ADS PubMed © 2002 The American Association for Clinical Chemistry This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
TI - Maternal Nitric Oxide Supplementation Decreases Cord Blood S100B in Intrauterine Growth-retarded Fetuses
JF - Clinical Chemistry
DO - 10.1093/clinchem/48.4.647
DA - 2002-04-01
UR - https://www.deepdyve.com/lp/oxford-university-press/maternal-nitric-oxide-supplementation-decreases-cord-blood-s100b-in-VbRt1s0SmC
SP - 647
VL - 48
IS - 4
DP - DeepDyve
ER -